Vera Therapeutics
VERA
84 hedge funds and large institutions have $538M invested in Vera Therapeutics in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 38 increasing their positions, 15 reducing their positions, and 8 closing their positions.
153% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 15
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
11% more funds holding
Funds holding: 76 → 84 (+8)
2.44% more ownership
Funds ownership: 86.14% → 88.58% (+2.4%)
12% less capital invested
Capital invested by funds: $612M → $538M (-$73.7M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$19.7M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$13.9M |
| 3 |
Axa
Paris,
France
|
+$4.65M |
| 4 |
ACM
Altium Capital Management
New York
|
+$3.67M |
| 5 |
BlackRock
New York
|
+$3.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.7M |
| 2 |
CG
Carlyle Group
Washington,
District of Columbia
|
-$16.8M |
| 3 |
Millennium Management
New York
|
-$5.36M |
| 4 |
EP
Eversept Partners
New York
|
-$4.5M |
| 5 |
O
OrbiMed
New York
|
-$4.1M |
VERA Hedge Fund Activity: Q3 2023 in Review
84 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q3 2023, worth a combined $538M — down 12% from $612M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new VERA positions and 8 closed out — a net gain of 9 holders — while 38 added to existing stakes and 15 trimmed.
The largest buyer was State Street, adding an estimated $19.7M. The largest seller was Fidelity Investments, cutting an estimated $18.7M.
- 84 institutional investors held Vera Therapeutics (VERA) as of Q3 2023, up from 76 in Q2 2023.
- Funds reported $538M of Vera Therapeutics stock for Q3 2023, down 12% quarter-over-quarter.
- 17 funds opened new Vera Therapeutics positions in Q3 2023 and 8 closed out, a net change of +9 holders.
- The largest Vera Therapeutics buyer in Q3 2023 was State Street, an estimated $19.7M added.
- The largest Vera Therapeutics seller in Q3 2023 was Fidelity Investments, an estimated $18.7M sold.
Based on aggregated 13F filings for Q3 2023.